AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
